H.G. Infra Engineering Sets 12 August 2026 as Dividend Record Date
H.G. Infra Engineering (HGINFRA) has informed the NSE that 12 August 2026 will be the record date for dividend eligibility.
Read articleAI-assisted articles on quarterly results, exchange filings, and earnings calls — tied to the companies you follow.
288 articles published
Results for “BIL” · in Market Updates — Clear filters
H.G. Infra Engineering (HGINFRA) has informed the NSE that 12 August 2026 will be the record date for dividend eligibility.
Read articleBoard Meeting 1) Audited Standalone and Consolidated financial results for the quarter and Year ended 31st March 2026. As per Regulation 33 of Listing Regulations, the Financial Results, statement of Assets & Liabilities and Audited Report with Declaration for Non-Applicability of Statement of Impact of Audit Qualification. 2) Appointed M/s. Ashok K. Bhatt & Co. as the Internal Auditor of the Company for the FY 2026-2027. Brief Profile of the Internal Auditor are attached herewith 1) Aud
Read articleCompany Update Non- Applicability of Annual Secretarial Compliance Report for the Financial Year ended 31.03.2026 under Regulation 24A of the SEBI (LODR) Regulations, 2015. Unisem Agritech Limited is claiming exemption under Regulation 15(2) of the Chapter IV of SEBI (LODR), Regulations 2015 as: (b) The listed entity which has listed its securities on the SME Exchange. In View of the above, relaxation is provided to SME listed Companies under Reg 15(2) of SEBI(LODR) Regulations, 2015
Read articleCompany Update Non- Applicability of Annual Secretarial Compliance Report for the Financial Year ended 31.03.2026 under Regulation 24A of the SEBI (LODR) Regulations, 2015. Unisem Agritech Limited is claiming exemption under Regulation 15(2) of the Chapter IV of SEBI (LODR), Regulations 2015 as: (b) The listed entity which has listed its securities on the SME Exchange. In View of the above, relaxation is provided to SME listed Companies under Reg 15(2) of SEBI(LODR) Regulations, 2015
Read articleOthers Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. May 28, 2026, has, inter alia: 1. Accepted the resignation of M/s R S Dani & Co., Chartered Accountants, as Statutory Auditor of the Company due to expiration of peer review certificate of his firm and his inability to sign and conduct audit for
Read articleOthers Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. May 28, 2026, has, inter alia: 1. Accepted the resignation of M/s R S Dani & Co., Chartered Accountants, as Statutory Auditor of the Company due to expiration of peer review certificate of his firm and his inability to sign and conduct audit for
Read articleCompany Update Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Read articleBoard Meeting 1. Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026, we submit herewith: a) the Auditor's Report on Standalone & Consolidated Financial Results issued by our Statutory Auditors M/s SS Kothari Mehta & Co. LLP, Chartered Accounts b) Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2026 c) Audited Statement of Assets and Liabilities as on March 31, 2026 d)
Read articlePress Release Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority
Read articleIpca Laboratories (IPCALAB) has made the transcript of its latest earnings conference call available on the NSE exchange. Investors can review management insights.
Read articleOlympic Management & Financial Services (BSE: OLYMTFI) has announced a book closure for its 42nd Annual General Meeting, with the register of members remaining shut from September 18 to September 24, 2026.
Read articleZelio E Mobility's Q4 FY26 earnings call took place on May 29, 2026, though the transcript header contains no financial figures or guidance for investors.
Read articleShreeji Shipping Global Limited has received Income Tax Department approval to opt into the Tonnage Tax Scheme under Chapter XII-G of the Income-tax Act, 1961, effective from FY 2025-26.
Read articleNSE & BSE filings, quarterly results, insider trades, and smart volume alerts — delivered on WhatsApp or Telegram. No separate app to install.
Need more? Pro tracks up to 500 companies with preferential issue alerts.
No credit card required. Connect WhatsApp or Telegram in minutes.